Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy
- PMID: 39775109
- PMCID: PMC11706851
- DOI: 10.1007/s00415-024-12740-3
Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy
Abstract
Background: With the approval of disease-modifying treatments for 5q-spinal muscular atrophy (SMA), there is an increasing need for biomarkers for disease course and therapeutic response monitoring. Radially sampled Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA) MR-imaging enables spinal cord (SC) gray matter (GM) delineation and quantification in vivo. This study aims to assess SC GM atrophy in patients with 5q-SMA and its associations with clinical disability.
Methods: Twenty-one patients with 5q-SMA and twenty-one age- and sex-matched healthy controls (HCs) prospectively underwent 3 T axial 2D-rAMIRA MR-imaging at the intervertebral disc levels C2/C3-C5/C6 and Tmax (lumbar enlargement level). Associations between SC GM areas with muscle strength tested by dynamometry, Motor Function Measure (MFM), revised upper limb module (RULM), Revised Hammersmith Scale (RHS), and SMA-Functional Rating Scale (SMA-FRS) were assessed by Spearman Rank correlations and linear regression analysis.
Results: Compared to HCs, patients had significantly reduced SC GM areas at levels C3/C4 (relative reduction (RR) = 13.6%, p < 0.0001); C4/C5 (RR = 16.7%, p < 0.0001), C5/C6 (RR = 17.1%, p < 0.0001), and Tmax (RR = 17.4%, p < 0.0001). Significant correlations were found between cervical SC GM areas and muscle strength, RULM, MFM, RHS, and SMA-FRS. In linear regression analysis, GM area C3/C4 explained 33% of RHS variance.
Conclusion: SC GM atrophy is detectable in patients with 5q-SMA and is consistently associated with clinical measures of upper limb function, physiotherapeutic assessments, and SMA-FRS indicating the clinical relevance of the observed atrophy. Further longitudinal investigations are necessary next steps to evaluate this novel and easily applicable imaging marker as a potential disease course and therapeutic response marker.
Keywords: Magnetic resonance imaging; SMA; Spinal cord atrophy; Spinal cord imaging; Spinal muscular atrophy.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: None of the other co-authors (EMK, MJW, CW, LS, MWei, TH, DF, NB, MWeb, MS, and OB) has a conflict of interest with respect to this study. Ethical approval: The local ethics committee approved the study (EKNZ 2019–01228). All participants gave written informed consent before participation in this study. The study is registered at clinicaltrials.gov: NCT06137612.
Figures


Similar articles
-
Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis.Eur J Neurol. 2024 Jun;31(6):e16268. doi: 10.1111/ene.16268. Epub 2024 Mar 11. Eur J Neurol. 2024. PMID: 38465478 Free PMC article.
-
Measurement of spinal cord atrophy using phase sensitive inversion recovery (PSIR) imaging in motor neuron disease.PLoS One. 2018 Nov 29;13(11):e0208255. doi: 10.1371/journal.pone.0208255. eCollection 2018. PLoS One. 2018. PMID: 30496320 Free PMC article.
-
Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome.Eur J Neurol. 2022 May;29(5):1435-1445. doi: 10.1111/ene.15261. Epub 2022 Mar 3. Eur J Neurol. 2022. PMID: 35102676 Free PMC article.
-
Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis.Neuromuscul Disord. 2022 Mar;32(3):185-194. doi: 10.1016/j.nmd.2021.12.005. Epub 2022 Jan 4. Neuromuscul Disord. 2022. PMID: 35115230
-
Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.Neurotherapeutics. 2022 Mar;19(2):464-475. doi: 10.1007/s13311-022-01200-3. Epub 2022 Feb 17. Neurotherapeutics. 2022. PMID: 35178673 Free PMC article.
Cited by
-
Quantitative cervical cord MRI in spinal muscular atrophy: a sensitive imaging biomarker of disease evolution and treatment.J Neurol. 2025 Jun 24;272(7):475. doi: 10.1007/s00415-025-13205-x. J Neurol. 2025. PMID: 40553176 Free PMC article.
References
-
- Brzustowicz LM, Lehner T, Castilla LH et al (1990) Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2–13.3. Nature 344(6266):540–541. 10.1038/344540a0 - PubMed
-
- Melki J, Abdelhak S, Sheth P et al (1990) Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 344(6268):767–768. 10.1038/344767a0 - PubMed
-
- Melki J, Sheth P, Abdelhak S et al (1990) Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators. Lancet Lond Engl. 336(8710):271–273. 10.1016/0140-6736(90)91803-i - PubMed
-
- Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS (2022) Spinal muscular atrophy. Nat Rev Dis Primer 8(1):52. 10.1038/s41572-022-00380-8 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous